India te Novavax para Emergency Use nemite hotishe

New Delhi: US-based vaccine maker Novavax para India te emergency samai jolaboli filed submissions korishe koishe. Etu submission  toh Drugs Controller General of India (DCGI) ke tai laga partner Serum Institute of India (SII) logot thishe. Serum Institute of India (SII) toh itya India te Covishield vaccine bona company ase aro itya India te etu laga vaccine toh manuh ke thi-ase. India jarikena Novavax toh Indonesia aro Philippines te be COVID-19 vaccine emergency neshina jolai ase. Etu moina kotom howa samai US vaccine maker para World Health Organization logot COVAX global vaccine programme te part loboli hotiboli bapana kori ase koishe. Novavax CEO Stanley Erck para etu submissions toh “important step ase aro desh sob te millions doses toh safe aro effective hoikena bemari toh rokaboli paribo.” Koishe. India te US pharma giant toh Serum Institute of India logot partnered hoikena vaccine bonabo aro bekabo. Novavax aro SII para COVAX Facility logot 1.1 billion doses oper thiboli koikena ase. Novavax two-dose vaccine, branded Covovax toh Covishield logot olop para daam wala hobo, koikena CEO para June moina te NDTV logot interview te koikena ase. Mr Erck para aro koishe ke, Covovax toh Covid variants te be kam koriboli paribo, etu laga data para Delta variant te keman bhal kam koribo etu toh kuboli naparikena ase. Novavax para Covid bemari oper te 90 per cent effectiveness thikai ase aro Delta variant nemite aro data besi laki ase koishe.